The stock market has been a mixed bag for investors these past few weeks. The S&P 500 has risen roughly 6% since June, however a lot of the high-flying growth stocks have been beaten down. This indicates a shift in investor preference to stable blue-chip stocks. One such stock I believ
&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-83950254&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/83950254/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Didcot Power Station, in the U.K. (Photo by Matt Cardy/Getty Images)
The best-performing energy commodity over the past year is not oil or gas &a;ndash; it is carbon allowances from the European Union&a;rsquo;s carbon market, the EU Emissions Trading Scheme (EU ETS).
The price of a tonne of carbon emitted under the ETS is now nudging &a;euro;15 (it was &a;euro;14.35 at....More>>>
If there is such a thing as an investing rut, I often worry that I’m in one. As a relatively new investor, I max out my IRA every year, but that’s about all I do. There is no second tier to my investing process, so I have been trying to learn more about other means of investing in hopes that I will invest more, or at least strengthen my current investments in the new year.
I think a lot of young professionals are unsure of where to put their money beyond the 401(k). If you’re someone who has resolved to become a better investor in 2017, here are some starter tips. To....More>>>
“Formula for success: rise early, work hard, strike oil” – J. Paul Getty
I must confess to feeling kind of lonely at times this year being one of a handful of observers of the casino space, (and at times, the only one,) standing firm on my undiminished faith that Las Vegas Sands (NYSE:LVS) valuations were dead wrong. Now, after the Macau Parisian has opened and LVS Q3 results knocked it out of the park I suddenly have lots of company. I’m bemused to see the bandwagon suddenly getting rather crowded.
There’s no room for gloat or vapid vainglory in my....More>>>
Two big events on the horizon are Federal Reserve Chairwoman Janet Yellen speaking before Congress and the launch of earnings season with reports coming out from big banks. But until those get under way, investors are paying attention to whether the tech sector can follow through with a recent gain and whether oil prices can pull out of a slump.
On Friday, stocks finished higher for the session and week on the back of a rebound in tech stocks with the Dow Jones Industrial Average
Digit uses text messaging and humor to communicate with Millennial users. (Photo credit: Digit)
Digit, a popular app that automates savings for its users, will soon begin charging a monthly fee in what will amount to a major test of its Millennial fan base.
The app, which monitors the activity in your bank account and diverts small amounts into savings, has decided to start charging $2.99 a month. There will be a 100-day free trial that will give users a chance to decide if the app is worth paying for or not. The clock starts ticking for existing....More>>>
Shares of Novavax (NASDAQ:NVAX) were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-
Gilead Sciences, Inc.’s (GILD Quick QuoteGILD ) wholly owned subsidiary, Kite, announced that the European Commission (“EC”) has approved its chimeric antigen receptor (CAR) T-cell therapy, Yescarta (axicabtagene ciloleucel) for the treatment of diffuse large B-cell l
Ispolink (CURRENCY:ISP) traded 17.7% lower against the dollar during the 1 day period ending at 22:00 PM E.T. on September 7th. One Ispolink coin can now be bought for approximately $0.0035 or 0.00000007 BTC on major cryptocurrency exchanges. Ispolink has a market capitalization of $5.57
Bristol Myers Squibb (BMY Quick QuoteBMY ) announced that its blockbuster drug Opdivo (nivolumab), as an injection for intravenous use, has received approval from the FDA to treat adjuvant patients with urothelial carcinoma (“UC”) who are at high risk of recurrence after un